MTA2 has been linked to tumour invasion depth, regional lymph node metastasis, distant metastasis, and poor long-term survival rates independent of age or gender in patients with esophageal squamous cell carcinoma [29], gastric cancer [13], non-small-cell lung cancer [30], and colorectal cancer [31]. Here, MTA2 is linked to non-small cell lung carcinoma.